Neville Rodie & Shaw Inc. Purchases 1,953 Shares of Zoetis Inc. (ZTS)

Neville Rodie & Shaw Inc. boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 1.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 142,519 shares of the company’s stock after acquiring an additional 1,953 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Zoetis were worth $9,087,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in shares of Zoetis by 8.2% during the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after acquiring an additional 389,260 shares during the period. Swiss National Bank increased its stake in shares of Zoetis by 8.1% during the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after acquiring an additional 133,900 shares during the period. Gladstone Capital Management LLP acquired a new position in shares of Zoetis during the second quarter valued at approximately $3,134,000. Victory Capital Management Inc. increased its stake in shares of Zoetis by 13.9% during the second quarter. Victory Capital Management Inc. now owns 277,641 shares of the company’s stock valued at $17,320,000 after acquiring an additional 33,894 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares during the period. 93.54% of the stock is currently owned by institutional investors.

Zoetis Inc. (NYSE:ZTS) traded up 0.86% on Friday, hitting $64.29. 1,381,405 shares of the stock traded hands. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $66.35. The firm’s 50 day moving average is $64.54 and its 200 day moving average is $61.63. The stock has a market cap of $31.44 billion, a price-to-earnings ratio of 36.34 and a beta of 1.02.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Equities analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a $0.105 dividend. This represents a $0.42 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is 23.73%.

COPYRIGHT VIOLATION NOTICE: “Neville Rodie & Shaw Inc. Purchases 1,953 Shares of Zoetis Inc. (ZTS)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/neville-rodie-shaw-inc-acquires-1953-shares-of-zoetis-inc-zts.html.

Several research analysts have issued reports on the stock. BMO Capital Markets set a $65.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a research note on Wednesday. BidaskClub lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Thursday. Stifel Nicolaus reissued a “buy” rating and set a $65.00 target price on shares of Zoetis in a research note on Tuesday. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 target price on shares of Zoetis in a research note on Tuesday. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $62.00 target price on shares of Zoetis in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $65.76.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply